Clinical trial
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic…
NCT00419250 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00419250 |
|---|---|
| Title | A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia |
| Official title | A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia, Leukemia, B-Cell, Chronic |
| Intervention type | Drug |
| Interventions | lenalidomide |
| Enrollment | 52 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Jan 8, 2007 |
| Last update posted | Nov 8, 2019 |
| Countries | Canada, Germany, Italy, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: